Ebglyss

Ebglyss is used to treat moderate-to-severe atopic dermatitis. It addresses the inflammation caused by eczema all over your body, resulting in persistently dry, itchy, and irritated skin.

Molecule Details :

  • Molecule Name :

    Lebrikizumab-Lbkz
  • Innovator :

    ELI LILLY
  • Approval Date :

    13-Sep-24
  • Data Exclusivity Expiry :

    13-Sep-28
  • Market Exclusivity Expiry :

    13-Sep-36
  • Dosage Form :

    Prefilled Pen Subcutaneous Injection
  • Strength :

    250mg
  • Therapeutic Category :

    Immunomodulators
  • Revenue ($M) :

    79

Year-wise Projected Sales ($M) :

  • 2025 :

    423
  • 2026 :

    906
  • 2027 :

    1,278
  • 2028 :

    1,694
  • 2029 :

    2,153
  • 2030 :

    2,493
  • 2031 :

    2,819
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?